Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Cbl-b Inhibitor
NX-1607 · 1 trial · 14 indications
Phase 1a
Phase 1a
Phase 1b
| Arm | Type | Description |
|---|---|---|
| Phase 1a Dose Escalation of NX-1607 (monotherapy) | EXPERIMENTAL | Multiple dose levels and dosing regimen of NX-1607 to be evaluated; determination of MTD/Phase 1b recommended dose. |
| Phase 1a Food Effect | EXPERIMENTAL | Impact of food on NX-1607 bioavailability and tolerability to be evaluated |
| Phase 1b Dose Expansion in platinum-resistant EOC | EXPERIMENTAL | Patients with platinum-resistant EOC, including primary peritoneal and fallopian tube carcinoma |
| Phase 1b Dose Expansion in advanced gastric/GEJ cancer | EXPERIMENTAL | Patients with recurrent, locally advanced, or metastatic gastric or GEJ adenocarcinoma |
| Phase 1b Dose Expansion in HNSCC | EXPERIMENTAL | Patients with recurrent, locally advanced, or metastatic HNSCC |
| Phase 1b Dose Expansion in recurrent melanoma | EXPERIMENTAL | Patients with recurrent and either metastatic or unresectable Melanoma |
| Phase 1b Dose Expansion in advanced NSCLC | EXPERIMENTAL | Patients with Stage IV NSCLC |
| Phase 1b Dose Expansion in mCRPC | EXPERIMENTAL | Patients with mCRPC who received a minimum of 2 prior lines of therapy in the advanced setting including androgen receptor-directed therapy and a taxane-based chemotherapy and has PSA or radiographic progression |
| Phase 1b Dose Expansion in mixed solid tumor cohort | EXPERIMENTAL | Cohort of mixed solid tumor indications consisting of patients with MPM, TNBC, locally advanced or metastatic urothelial cancer, cervical cancer, or DLBCL/DLBCL-RT |
| Phase 1a Dose Escalation of NX-1607 in combination with Paclitaxel | EXPERIMENTAL | Indications may include but are not limited to, platinum resistant EOC, gastric/GEJ cancer. HSNCC, NSCLC, TNBC, locally advanced or metastatic urothelial cancer and cervical cancer. |
| Phase 1b Dose Expansion of NX-1607 in combination with Paclitaxel | EXPERIMENTAL | Indications may include but are not limited to, platinum resistant EOC, gastric/GEJ cancer, HSNCC, NSCLC, TNBC, and locally advanced or metastatic urothelial cancer and cervical cancer |
| Phase 1b Dose Expansion in MSS CRC | EXPERIMENTAL | Patients with histologically confirmed MSS CRC, known KRAS WT, and must have been previously treated with \> = 2 lines of systemic therapy including a fluoropyrimidine, irinotecan, and/or oxaliplatin (and EGFR inhibitor if known Ras wild type) |
| Name | Type | Description |
|---|---|---|
| NX-1607 | DRUG | Oral NX-1607 |
| Paclitaxel | DRUG | Paclitaxel IV |
Key Inclusion Criteria: * Age ≥ 18 years. * Measurable disease per disease-specific response criteria. * Patients must have disease that is metastatic or unresectable and have received standard treatment options, are not candidates for standard treatment options, or will otherwise be prevented from...
NX-1607 is an investigational small molecule drug being developed by Nurix Therapeutics, Inc. for the treatment of advanced cancers, including epithelial ovarian cancer. It is currently in Phase 1 clinical development and has not been approved by the FDA. It is being studied in adults with advanced malignancies.
NX-1607 is being studied for the treatment of advanced solid tumors and blood cancers, including epithelial ovarian cancer, gastric cancer, gastroesophageal junction cancer, head and neck squamous cell carcinoma, melanoma, non-small cell lung cancer, metastatic castration-resistant prostate cancer, malignant pleural mesothelioma, triple negative breast cancer, metastatic urothelial carcinoma, cervical cancer, diffuse large B cell lymphoma, Richter transformation, and microsatellite stable colorectal carcinoma.
NX-1607 targets CBL-B, an E3 ubiquitin ligase that acts as a negative regulator of immune cell activation. By inhibiting CBL-B, NX-1607 is designed to enhance T-cell and natural killer cell activation against tumor cells. This mechanism is intended to boost the body's immune response to cancer.
NX-1607 is being developed by Nurix Therapeutics, Inc., a biopharmaceutical company focused on targeted protein degradation and modulation. Nurix Therapeutics trades on the Nasdaq under the ticker symbol NRIX. The company is the sponsor of the ongoing Phase 1 clinical trial evaluating NX-1607 in patients with advanced malignancies.
NX-1607 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA for any indication. The Phase 1 trial is currently recruiting participants and is designed to evaluate the safety, tolerability, and preliminary activity of NX-1607 in adults with advanced cancers.
NX-1607 is being evaluated in a Phase 1 clinical trial, NCT05107674, titled A Study of NX-1607 in Adults With Advanced Malignancies. The trial is currently recruiting and has an estimated enrollment of 345 participants. It is being conducted in the United States and the United Kingdom and includes patients with a range of advanced solid tumors and lymphomas.